AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine

Francois Lux 1, 2 Vu Long Tran 1 Eloise Thomas 1 Sandrine Dufort 2 Fabien Rossetti 1 Matteo Martini 1 Charles Truillet 3 Tristan Doussineau 2 Guillaume Bort 1 Franck Denat 4 Frédéric Boschetti 5 Goran Angelovski 6 Alexandre Detappe 7 Yannick Crémillieux 8 Nathalie Mignet 9, 10, 11, 12, 13 Bich-Thuy Doan 9, 10, 11, 12, 13 Benoit Larrat 14 Sébastien Mériaux 14 Emmanuel Barbier 15 Stéphane Roux 16 Peter Fries 17 Andreas Müller 17 Marie-Caline Abadjian 18 Carolyn Anderson 18 Emmanuelle Canet-Soulas 19 Penelope Bouziotis 20 Muriel Barberi-Heyob 21 Céline Frochot 22 Camille Verry 23 Jacques Balosso 23 Michael Evans 24 Jacqueline Sidi-Boumedine 25 Marc Janier 25 Karl Butterworth 26 Stephen Mcmahon 26 Kevin Prise 26 Marie-Thérèse Aloy 27, 28 Dominique Ardail 27, 28 Claire Rodriguez-Lafrasse 27, 28 Erika Porcel 29 Sandrine Lacombe 29 Ross Berbeco 7 Awatef Allouch 30 Jean-Luc Perfettini 30, 31 Cyrus Chargari 32 Eric Deutsch 33 Géraldine Le Duc 2 Olivier Tillement 1, 2
23 Equipe 6 : Rayonnement synchrotron et Recherche Médicale
UJF - Université Joseph Fourier - Grenoble 1, CEA - Commissariat à l'énergie atomique et aux énergies alternatives, INSERM - Institut National de la Santé et de la Recherche Médicale : U836, [GIN] Grenoble Institut des Neurosciences
27 PRISME - PRISME
IPNL - Institut de Physique Nucléaire de Lyon
32 Curiethérapie
Département de radiothérapie [Gustave Roussy]
Abstract : AGuIX® are sub-5 nm nanoparticles made of a polysiloxane matrix and gadolinium chelates. This nanoparticle has been recently accepted in clinical trials in association with radiotherapy. This review will summarize the principal preclinical results that have led to first in man administration. No evidence of toxicity has been observed during regulatory toxicity tests on two animal species (rodents and monkeys). Biodistributions on different animal models have shown passive uptake in tumours due to enhanced permeability and retention effect combined with renal elimination of the nanoparticles after intravenous administration. High radiosensitizing effect has been observed with different types of irradiations in vitro and in vivo on a large number of cancer types (brain, lung, melanoma, head and neck…). The review concludes with the second generation of AGuIX nanoparticles and the first preliminary results on human.
Complete list of metadatas

https://hal.archives-ouvertes.fr/hal-01935540
Contributor : Noémie Thomas <>
Submitted on : Monday, November 26, 2018 - 5:35:22 PM
Last modification on : Thursday, August 22, 2019 - 12:10:38 PM
Long-term archiving on : Wednesday, February 27, 2019 - 2:55:28 PM

File

Lux, BRJ, 2018.pdf
Publisher files allowed on an open archive

Identifiers

Citation

Francois Lux, Vu Long Tran, Eloise Thomas, Sandrine Dufort, Fabien Rossetti, et al.. AGuIX® from bench to bedside—Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, British Institute of Radiology, 2019, 92 (1093), pp.20180365. ⟨10.1259/bjr.20180365⟩. ⟨hal-01935540⟩

Share

Metrics

Record views

1130

Files downloads

529